Somatostatin analogues
The invention provides cyclo[{4-(NH 2 —C 2 H 4 —NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.
1. A compound of formula
where one of the amino groups being optionally in protected form, or a salt or complex thereof.
2. A compound according to claim 1 in unprotected form, in salt form.
3. A compound according to claim 2 as a mono- or disalt.
4. A compound according to claim 3 in the form of an acetate, benzoate, aspartate or pamoate salt.
5. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof, in association with one or more pharmaceutically acceptable diluent(s) or carrier(s) therefor.
6. A pharmaceutical composition according to claim 5 , in a sustained release form or in a topical form.
7. A pharmaceutical composition according to claim 5 , for use in combination with an immunosuppressive agent, an anti-inflammatory agent, a GH secretagogue receptor modulating agent, a GH receptor antagonist, an insulin secretagogue, an insulin secretion enhancer, an insulin sensitizer, a low dose of insulin, an agent having anti-angiogenetic effects or a chemotherapeutic agent.
8. A compound of formula
where one of the amino groups being optionally in protected form, or a salt or complex thereof and R 1 is a chelating agent, optionally complexed with a detectable or a radiotherapeutic element.